DermaGen Overview

  • Founded
  • 2004
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

DermaGen General Information


Developer of antimicrobial peptides directed against skin microbes. The company develops peptides which exert potent antimicrobial effects and are derived from endogenous human proteins, such as those of the complement system, as well as several other skin and blood-derived proteins.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Scheelevägen 22
  • SE-223 63 Lund
  • Sweden
+46 046-19 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DermaGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Dec-2010 00.000 Completed Generating Revenue
2. Early Stage VC 02-Apr-2008 00.000 00.000 Completed Startup
1. Corporate Completed Startup
To view DermaGen’s complete valuation and funding history, request access »

DermaGen Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Karolinska Development Venture Capital Minority 000 0000 000000 0
LU Innovation Corporate Venture Capital Minority 000 0000 000000 0
Midroc Invest Venture Capital Minority 000 0000 000000 0
Östersjöstiftelsen Government Minority 000 0000 000000 0
To view DermaGen’s complete investors history, request access »

DermaGen Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 00000 00 00.000 Drug Discovery
To view DermaGen’s complete investments history, request access »

DermaGen Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 00000 00000 00 00.000 Completed
  • 3 buyers
To view DermaGen’s complete exits history, request access »